Physician profile
David Laurence Cobb
NPI 1811949365
$844.13
in general payments reported to CMS, 2019-2025
17 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $18.26 · 2022: $56.25 · 2023: $178 · 2024: $99.48 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $206.38 | 2019-2025 | Liletta |
| Pfizer INC. | $124.00 | 2019-2023 | |
| Astellas Pharma US INC | $95.87 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $62.06 | 2023-2025 | |
| Avion Pharmaceuticals | $56.82 | 2019-2023 | Balcoltra |
| Coopersurgical, INC. | $55.31 | 2019-2025 | Paragard T 380a |
| Stryker Corporation | $43.63 | 2025 | Clottriever Bold Catheter, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Hologic Sales and Service, LLC | $31.06 | 2019-2020 | |
| Exact Sciences Corporation | $30.02 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Exeltis, USA INC. | $27.03 | 2024-2025 | Slynd |
| Sumitomo Pharma America, INC. | $24.59 | 2023 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $22.66 | 2025 | |
| Millicent US INC | $21.08 | 2025 | Intrarosa, Femlyv |
| Biogen, INC. | $19.45 | 2024 | |
| Allergan, INC. | $13.02 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $11.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.